SRR934825
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 9.494086727989487
- age_years
- 61
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.549
- ANGIOGENESIS+0.504
- IL6_JAK_STAT3_SIGNALING+0.476
- UNFOLDED_PROTEIN_RESPONSE+0.465
- INTERFERON_GAMMA_RESPONSE+0.462
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.461
- INTERFERON_ALPHA_RESPONSE+0.443
- MTORC1_SIGNALING+0.413
- TNFA_SIGNALING_VIA_NFKB+0.407
- TGF_BETA_SIGNALING+0.379
Top 10 suppressed
- KRAS_SIGNALING_DN-0.388
- SPERMATOGENESIS-0.208
- PANCREAS_BETA_CELLS-0.170
- MYOGENESIS-0.125
- OXIDATIVE_PHOSPHORYLATION-0.073
- HEDGEHOG_SIGNALING-0.027
- ESTROGEN_RESPONSE_LATE-0.001
- XENOBIOTIC_METABOLISM+0.002
- BILE_ACID_METABOLISM+0.013
- CHOLESTEROL_HOMEOSTASIS+0.015
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934875 | — | — | 0.962 |
| 2 | SRR934816 | — | — | 0.960 |
| 3 | SRR934926 | — | — | 0.957 |
| 4 | SRR934782 | — | — | 0.957 |
| 5 | SRR934829 | — | — | 0.954 |
| 6 | SRR934965 | — | — | 0.952 |
| 7 | C9EE359E-2F42-4D20-880D-FBF8B4953731 | — | — | 0.951 |
| 8 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.951 |
| 9 | SRR934932 | — | — | 0.949 |
| 10 | SRR934750 | — | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.549 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.504 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.476 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.465 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.462 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.461 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.443 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.413 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.407 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.379 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.374 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.359 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.356 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.356 | Inavolisib | — uncovered |
| APOPTOSIS | 0.348 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.334 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.332 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.306 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.295 | Inavolisib | — uncovered |